-
17 June 2025 18:01:33
- Source: Sharecast
PDMR Dealings
Oxford, UK - 17 June 2025: OXB (LSE: OXB) (the "Company"), a global quality and innovation-led cell and gene therapy CDMO, announces that Dr. Heather Preston, a Non-Executive Director of the Company, has purchased 11,389 ordinary shares of 50p each ("Ordinary Shares") in the Company on 17 June 2025 on the London Stock Exchange at a price of £3.24. Following this purchase, Dr. Heather Preston holds 29,687 shares representing 0.028% of the Company.
The below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.
|
1. |
Details of the Person Discharging Managerial Responsibility ("PDMR") |
|||||
|
a) |
Name |
Dr. Heather Preston |
||||
|
2. |
Reason for the notification |
|||||
|
a) |
Position/status |
Non-Executive Director
|
||||
|
b) |
Initial notification/ amendment |
Initial Notification |
||||
|
3. |
Details of the Issuer |
|||||
|
a) |
Name |
Oxford Biomedica plc |
||||
|
b) |
LEI code |
213800S1GVQNXQ15K851 |
||||
|
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
|
a) |
Description of the financial instrument
Identification code |
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43 |
||||
|
b) |
Nature of the transaction |
Purchase of shares |
||||
|
c) |
Currency |
GBP - British pound |
||||
|
d) |
Price(s) and volumes(s)
|
|
||||
|
e) |
Aggregated information - Aggregate volume - Aggregated total
|
11,389
£36,900.36 |
||||
|
f) |
Date of the transaction |
2025-06-17 |
||||
|
g) |
Place of the transaction |
London Stock Exchange (XLON) |
||||
-Ends-
Enquiries:
OXB:
Natalie Walter, Company Secretary - T: +44 (0) 1865 783 000 / E: cosec@oxb.com
ICR Healthcare:
T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com
Mary-Jane Elliott / Angela Gray / Davide Salvi
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of unique technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France and Bedford MA, US. Learn more at www.oxb.com, and follow us on LinkedIn and YouTube.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.